Biotech Startups

Deliver Biosciences develops a nanoparticle-based delivery platform to genetically engineer cells in patients for cell and gene therapies, targeting cancer immunotherapies as the first indication with applications in autoimmune, neurodegenerative, and cardiovascular diseases.

1 investor

DELiver Therapeutics develops small molecule and peptide therapeutics using high-throughput DNA encoded library (DEL) drug screening to address challenging and previously "undruggable" targets in clinical medicine, with a focus on tyrosine kinase targets. Its R&D facilities are located at K2Bio in Houston.

1 investor

Deliver Biosciences develops a nanoparticle-based delivery platform to genetically engineer cells inside patients (in vivo) for cell and gene therapies, using programmable targeting to transport payloads such as DNA and mRNA to specific cell types. Its first product targets T-cells to deliver a CAR gene for cancer immunotherapy, with longer-term applications in autoimmune, neurodegenerative, and cardiovascular diseases.

1 investor

Deliver Therapeutics develops small molecule and peptide therapeutics using DNA-encoded library screening to address difficult and previously undruggable clinical targets in medicine. The company focuses on discovering best-in-class and first-in-class drugs across oncology and other therapeutic areas.

1 investor

DelNova is a life science company developing proprietary assets in medical aesthetics and neuromuscular therapeutics, having advanced from early research into Series A financing. Its work relates to injectable aesthetics such as neurotoxins and peripheral nerve applications.

1 investor

Delox develops proprietary bio-decontamination solutions using solid-formulated hydrogen peroxide technology for healthcare, pharmaceutical, laboratory, and industrial environments where contamination control is critical. The company operates across Europe and North America, serving organizations in highly controlled settings that require precision decontamination with zero tolerance for failure.

1 investor

Delpharm is a contract development and manufacturing organization (CDMO) that develops and manufactures pharmaceutical products for the pharmaceutical industry across solid, sterile, semi-solid, and liquid dosage forms. With manufacturing sites across Europe and North America, the company ranks among the top 5 global CDMOs and specializes in pre-filled syringes, nasal sprays, and liquid pharmaceuticals.

1 investor

Delphian Tx is a clinical-stage biopharmaceutical company developing cannabinoid-based drugs (CBD:THC combinations) targeting the endocannabinoid system to treat migraine and other complex pain and CNS disorders. The company has a Phase 1 clinical trial ongoing and issued USPTO patents.

1 investor

Delphinium is a boutique clinical research organization (CRO) based in Groningen, Netherlands, that conducts early-phase clinical trials with a focus on healthy volunteers across therapeutic areas including cardiology, neurology, and metabolic diseases. The company operates its own clinical research unit with 12 beds and in-house pharmacy, offering services in pharmacokinetics/pharmacodynamics, first-in-human, and bioequivalence studies.

1 investor

Delta Life Science develops rapid, sensitive, and low-cost biosensor technology and instruments for analyzing biomarker concentrations in life sciences research and diagnostics. The company, which originated from TNO research, serves academic institutions and the pharmaceutical industry with tools for biomolecular interaction analysis.

1 investor

Deltamune manufactures registered and autogenous vaccines for poultry health, protecting birds against diseases including infectious coryza, egg drop syndrome, and salmonella infections. Operating from a GMP-certified facility in South Africa since 2008, the company serves poultry producers and veterinarians with custom vaccine solutions and commercial vaccine products.

1 investor

Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.

1 investor

Demeetra is a genome engineering company that develops precision gene-editing platforms — including Cas-CLOVER, Harbor-IN and Super piggyBac transposases and CleanCut CHO host cell lines — along with integrated cell line development and GMP manufacturing services. It serves biopharmaceutical developers through flexible licensing and service models for cell line development, biomanufacturing, and discovery programs.

1 investor

DENCODA develops DNA-based diagnostic assays that detect enzyme activity to identify diseases including osteoarthritis, kinase-related cancers, and protease-linked conditions. The company serves clinicians, researchers, and patients seeking early disease detection and diagnosis.

1 investor

DenovAI Biotech uses artificial intelligence and computational molecular biophysics to design proteins de novo, building platforms for rapid antibody discovery and bespoke high-affinity binders. The company targets therapeutic and diagnostic applications, including antibodies, peptide biologics, and diagnostic reporters for drug discovery.

1 investor

Denovo Sciences develops an AI platform for structure-based small-molecule drug discovery, using generative algorithms to design candidate molecules de novo within a target's binding pocket and predict their synthesizability and drug-likeness. It runs its own drug discovery programs and partners with others to identify small-molecule drug candidates, including work on broad-spectrum influenza inhibitors.

1 investor

De novo Biotherapeutics is a biotherapeutics company developing an mRNA platform to make high-end therapies more affordable. Its lead work focuses on mRNA-based engagers targeting relapsed or refractory cancers, with plans for phase 1 clinical studies.

1 investor

Dermala is a skincare company offering a personalized, FDA-approved acne treatment delivered as a monthly subscription kit that uses probiotics, prebiotics, and postbiotics to target acne-causing bacteria in the skin and gut microbiome. It applies big data, machine learning, and AI to tailor and optimize each customer's treatment based on their results.

1 investor

Dermaliq Therapeutics is a specialty pharmaceutical company developing topical dermatology therapies and medical skin care products based on its proprietary hyliQ drug-delivery platform, with a lead pipeline focused on hair loss conditions such as androgenetic alopecia and alopecia areata. Its candidates target delivery of active molecules into hair follicles and skin for patients with pattern hair loss, immune-mediated hair loss, and wound healing.

1 investor

Desentum is a clinical-stage biopharmaceutical company developing allergen immunotherapy products that reprogram immune responses to allergens toward tolerance. The company targets both respiratory and food allergies, with its lead asset currently in phase II clinical trials.

1 investor

DesiCorp develops advanced packaging and stabilization solutions for biopharmaceutical and therapeutic products, extending shelf-life without refrigeration to improve access in rural, remote, and emergency care settings. The company uses specialized materials and two-chambered packaging designs to preserve sensitive compounds during transport and storage in austere environments.

1 investor

1 investor

Detective Biosciences is developing a blood-based cancer detection test that analyzes patients' DNA epigenetic profiles. The company operates in the cancer diagnostics and biotech space.

1 investor

Detraxi is a privately held company developing emerging technology, seeking development funding and licensing partnerships. The page provides limited detail about the specific product or industry.

1 investor